Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -71.27M | -63.53M | -62.44M | -63.93M | -64.47M |
Total Depreciation and Amortization | 1.37M | 1.41M | 1.15M | 1.12M | 1.11M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 7.12M | 6.25M | 5.32M | 4.79M | 6.19M |
Change in Net Operating Assets | 173.00K | -2.08M | 98.00K | 556.00K | 5.10M |
Cash from Operations | -62.60M | -57.95M | -55.88M | -57.47M | -52.07M |
Capital Expenditure | -552.00K | -686.00K | -412.00K | -266.00K | -267.00K |
Sale of Property, Plant, and Equipment | 20.00K | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -532.00K | -686.00K | -412.00K | -266.00K | -267.00K |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 47.88M | 47.57M | 47.59M | 47.77M | 101.93M |
Repurchase of Common Stock | -- | -299.00K | -299.00K | -960.00K | -960.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 47.88M | 47.27M | 47.30M | 46.81M | 100.97M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -15.25M | -11.37M | -8.99M | -10.93M | 48.64M |